Facebook
X
LinkedIn
Forward
The Immunology of Obstructive Lung Disease and Emergence of Biologic Treatment
Program Overview
Asthma and COPD are common obstructive lung diseases that affect a large portion of the population. Although they share similar symptoms, their underlying pathophysiology differs, requiring distinct treatment strategies. Advances in biologic therapies underscore the importance of pulmonologists having a deeper understanding of lung immunobiology. This module is designed to address knowledge gaps in immunology, helping pulmonologists use biologics more effectively in clinical practice.
Target Audience
This educational activity is intended for pulmonary specialists and other members of the health care team who care for patients with obstructive lung diseases such as COPD and asthma.
Learning Objectives
Upon completion of this course, the learners should be able to:
- Recognize the underlying immunology associated with certain obstructive lung diseases
- Asses the barriers that have limited the use of biologic therapies to treat obstructive lung diseases and identify strategies to potentially overcome them
- Evaluate recent trial results for the use of biologics to treat obstructive lung diseases and consider the implications for clinical practice
Copyright Information
Copyright © 2025 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:
- The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
- Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.
Commercial Support Acknowledgment
This program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi, and Genentech, a member of the Roche Group.
Faculty
Stephanie Christenson, MD
Associate Professor, Medicine
Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine
UCSF Health
San Francisco, CA
Disclosures:
Amgen Inc, Apogee Therapeutics, Atheneum Consulting, Axon Advisors, Genentech, Kymera Therapeutics, Verona Pharma | Consultant
American Lung Association | Contract
AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi | Advisory Board
Devpro Pharma | Other Professional Activities
Nick Hanania, MD, MS
Director, Airways Clinical Research Center
Professor of Medicine
Chief, Section of Pulmonary, Critical Care and Sleep Medicine
Ben Taub Hospital
Baylor College of Medicine
Houston, TX
Disclosures:
Amgen, Inc, AstraZeneca, Chiesi USA, Inc, Genentech, GlaxoSmithKline, LLC, Regeneron Pharmaceuticals, Inc | Consultant
AstraZeneca, Sanofi | Advisory Board
AstraZeneca, GlaxoSmithKline, LLC | Contract
Elsevier Publishing | Other Securities
Frank Sciurba, MD
Professor of Medicine and Education
Director of Emphysema/COPD Research Center and Clinical Pulmonary Physiology Laboratories
University of Pittsburgh
Pittsburgh, PA
Disclosures:
AstraZeneca, Gaia Therapeutics, National Institutes of Health, Nuvaira, Patient-Centered Outcomes Research Institute, Pulmonx Corporation | Contract
GlaxoSmithKline, LLC, Sanofi, Verona Pharma | Consultant
Planning Committee
Sarah Bingel-McKillips
Senior Project Manager
The France Foundation
Old Lyme, CT
Disclosures:
Nothing to disclose
Stephanie Christenson, MD
Associate Professor, Medicine
Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine
UCSF Health
San Francisco, CA
Disclosures:
Amgen Inc, Apogee Therapeutics, Atheneum Consulting, Axon Advisors, Genentech, Kymera Therapeutics, Verona Pharma | Consultant
American Lung Association | Contract
AstraZeneca, GlaxoSmithKline, Regeneron Pharmaceuticals, Sanofi | Advisory Board
Devpro Pharma | Other Professional Activities
Nick Hanania, MD, MS
Director, Airways Clinical Research Center
Professor of Medicine
Chief, Section of Pulmonary, Critical Care and Sleep Medicine
Ben Taub Hospital
Baylor College of Medicine
Houston, TX
Disclosures:
Amgen, Inc, AstraZeneca, Chiesi USA, Inc, Genentech, GlaxoSmithKline, LLC, Regeneron Pharmaceuticals, Inc | Consultant
AstraZeneca, Sanofi | Advisory Board
AstraZeneca, GlaxoSmithKline, LLC | Contract
Elsevier Publishing | Other Securities
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures:
Nothing to disclose
Frank Sciurba, MD
Professor of Medicine and Education
Director of Emphysema/COPD Research Center and Clinical Pulmonary Physiology Laboratories
University of Pittsburgh
Pittsburgh, PA
Disclosures:
AstraZeneca, Gaia Therapeutics, National Institutes of Health, Nuvaira, Patient-Centered Outcomes Research Institute, Pulmonx Corporation | Contract
GlaxoSmithKline, LLC, Sanofi, Verona Pharma | Consultant
University of Pittsburgh
Pittsburgh, PA
Jennifer Siegel-Gasiewski, MPA
Director of Lifelong Learning
American Thoracic Society
New York, NY
Disclosures:
Nothing to disclose
Content Reviewer
Patrick Harty, PhD
Medical Director
The France Foundation
Old Lyme, CT
Disclosures:
Nothing to disclose
All relevant financial relationships listed have been mitigated
Accredited Provider
Provided by the American Thoracic Society
Developed in collaboration with the France Foundation.
Accreditation Statement – American Thoracic Society
"The American Thoracic Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.”
Physician Credit Designation (American Thoracic Society)
The American Thoracic Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
The France Foundation designates this activity for 1.0 contact hours.
Physician Associates
The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until July 1, 2026. PAs should only claim credit commensurate with the extent of their participation.
All other healthcare professionals completing this course will be issued a statement of participation.
Disclosure Policy
It is the policy of the ATS to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. As an accredited CME provider, the ATS requires that its planners, reviewers and presenters comply with the ACCME Standards Integrity and Independence in Accredited Continuing Education. The ATS also requires specific disclosure of relationships with companies and organizations associated with tobacco or cannabis and prohibits or limits participation of faculty in official ATS activities, including CME, if any tobacco industry relationship or some types of cannabis industry relationships is present. The most recent policies regarding potential conflicts of interest as well as the mechanisms to mitigate or resolve such conflicts can be found here: COI Policy for Official ATS Activities (thoracic.org)
Planning committee members, faculty, reviewers, and activity staff have disclosed the following relevant financial relationships. All relevant financial relationships listed have been mitigated.
Disclosure of Unlabeled Use:
ATS and TFF require CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. ATS and TFF do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™The American Thoracic Society designates this for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Participation
If you are requesting AMA credits or a certificate of participation, your certificate will be available for download.
CME Certificates of credit/attendance will be awarded based on the participant attending the activity, completing and submitting an evaluation and attesting to the credits earned. A CME certificate will be available upon successful completion.
All other healthcare professionals completing this course will be issued a certificate of participation.
The system keeps track of your progress. If you close the activity and resume it later, it will re-start where you left off.
Required Hardware/software
This site and its activities are best viewed using the latest versions of the Chrome, Edge, Firefox and Safari browsers.
Additionally, this site and its activities are best viewed using the latest Operating System for your device.